Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease.Clinical Gastroenterology and Hepatology. 2021;
- Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis.Hepatol Int. Mar. 2022; 23https://doi.org/10.1007/s12072-022-10319-6
- 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Journal of the American College of Cardiology. 2019; 74: e177-e232
- Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.Hepatol Res. Mar. 2022; : 30https://doi.org/10.1111/hepr.13764
- Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.Hepatology Research. 2022;
Publication stageIn Press Journal Pre-Proof
No funding was required for this study.
Conflicts of Interests
MN has been on the advisory board/consultant for 89BIO, Altimmune, Gilead, cohBar, Cytodyn, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Madrgial, NorthSea, Prespecturm, Terns, Siemens and Roche diagnostic; MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and Zydus; MN is a shareholder or has stocks in Anaetos, Chrownwell, Ciema, Rivus Pharma and Viking. All other authors have no conflict of interests.
Data were retrieved from the National Health and Nutrition Examination Survey Registry.
The study was conducted in accordance with the Declaration of Helsinki. The study was exempt from IRB review was no confidential patient information was involved.
All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. No writing assistance was obtained in the preparation of the manuscript. The manuscript, including related data, figures and tables has not been previously published and that the manuscript is not under consideration elsewhere. All authors approve the final version of the manuscript, including the authorship list and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.